Sign in
Not yet taking people in United StatesNo phase

ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma

Key facts

Who runs it
University of Colorado, Denver
Where
Aurora, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
120 people, planned
Starts
Jun 2027
Expected to end
Aug 2031
Type of study
Observational, 2 groups
Treatments tested
  • Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Provision to sign and date the consent form
  • Stated willingness to comply with all study procedures and be available for the duration of the study
  • Age ≥18 years
  • Histologically confirmed cervical or thoracic esophageal squamous cell carcinoma (ESCC). For cervical tumors (defined per NCCN as <5 cm from cricopharyngeus), the primary site must be the cervical esophagus rather than a primary hypopharyngeal malignancy as determined by the treating multidisciplinary team
  • Clinical stage cT1-4 or cTX, N0-3, M0 disease according to AJCC 8th Edition staging, based on available standard-of-care staging studies and treating investigator assessment. EUS is not required when nodal disease or other standard staging information is sufficient to support treatment with chemoradiotherapy
  • Planned treatment with curative-intent chemoradiotherapy, including either:
  • definitive chemoradiotherapy with surveillance intent, or neoadjuvant chemoradiotherapy with planned esophagectomy. Induction chemotherapy prior to chemoradiation is allowed, as well as the use of immunotherapy during the treatment course per physician discretion as part of curative-intent therapy
  • For thoracic or cervical ESCC, the planned radiation dose and fractionation must be consistent with a definitive chemoradiotherapy regimen according to institutional standards, regardless of whether treatment is delivered with neoadjuvant or definitive intent
  • Availability of pretreatment tumor tissue adequate for tumor-informed ctDNA assay generation
  • Ability to undergo protocol-specified peripheral blood collection for ctDNA analysis according to the assigned cohort, including mobile phlebotomy when applicable
  • ECOG performance status 0-2
  • Adequate baseline clinical evaluation completed per institutional standard, including staging PET/CT and endoscopic assessment

Who cannot take part

  • Prior thoracic radiotherapy overlapping planned treatment fields
  • Evidence of metastatic (M1) disease
  • Active second malignancy requiring systemic therapy that could confound ctDNA interpretation, except adequately treated non-melanoma skin cancer or localized malignancies under surveillance
  • Histology other than squamous cell carcinoma (including adenocarcinoma, small cell carcinoma, or mixed histology with predominant non-squamous features)
  • Inability to obtain adequate tumor tissue for ctDNA assay generation
  • Patients unable or unwilling to comply with serial blood collection or clinical follow-up requirements of either study cohort

Where in United States

  • University of Colorado HospitalAurora, United StatesContact: Chitra Pai KulyadiNot yet recruiting

About the trial

What the trial wants to find out

The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment.

Read full original descriptionShow less

Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance.

The main questions this study aims to answer are:

* Can ctDNA clearance after chemoradiotherapy predict 2-year complete response-disease-free survival? * Can ctDNA clearance improve the prediction of durable complete response compared with standard response assessment methods, including PET/CT and endoscopy? * Can ctDNA clearance at different timepoints during and after chemoradiotherapy help identify patients at risk of disease recurrence?

The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care.

Study participants will:

* Provide blood samples at baseline, during Week 3 of chemoradiotherapy, and at completion of chemoradiotherapy for ctDNA analysis. * Participate in one of two observational cohorts. Participants in the Longitudinal ctDNA Cohort will provide additional blood samples at 6 weeks and 3 months after chemoradiotherapy and every 3 months through 24 months. Participants in the Limited-Sampling Research Cohort will provide only three protocol-required blood samples. * Continue standard-of-care cancer treatment and follow-up according to treating physician discretion. * Allow researchers to review medical records to assess treatment response, cancer recurrence, salvage therapy, and survival status through 24 months after completion of chemoradiotherapy.

Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort.

This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.

The 2 groups in the trial

  • CLEAR-ESO Longitudinal ctDNA Cohort

    The Longitudinal ctDNA Cohort additionally obtains ctDNA at 6 weeks post-CRT, 3 months post-CRT, and every 3 months through 24 months, and physician decision-impact surveys assess whether ctDNA findings influence clinical management.

    Treatment: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)

  • CLEAR-ESO Limited-Sampling Research Cohort

    Participants in the Limited-Sampling Research Cohort undergo tumor-informed ctDNA assessment at baseline, Week 3 of CRT, and completion of CRT. Results are returned through routine clinical workflows. No physician decision-impact surveys are administered, and no protocol-directed ctDNA collections occur after completion of CRT. Clinical outcome data are collected through approximately 24 months following CRT.

    Treatment: Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CLEAR-ESO: ctDNA CLEARance to Predict Successful Non-operative Management and Pathologic Complete Response in ESOphageal Squamous Cell Carcinoma
Record updated
16 November 2026